GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProtoKinetix Inc (OTCPK:PKTX) » Definitions » Net Issuance of Preferred Stock

PKTX (ProtoKinetix) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is ProtoKinetix Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

ProtoKinetix's net issuance of preferred for the three months ended in Dec. 2024 was $0.00 Mil. The number is 0, which means that ProtoKinetix has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

ProtoKinetix's net issuance of preferred for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

ProtoKinetix Net Issuance of Preferred Stock Historical Data

The historical data trend for ProtoKinetix's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProtoKinetix Net Issuance of Preferred Stock Chart

ProtoKinetix Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Issuance of Preferred Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ProtoKinetix Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Issuance of Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

ProtoKinetix Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProtoKinetix Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of ProtoKinetix's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

ProtoKinetix Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProtoKinetix Inc (OTCPK:PKTX) » Definitions » Net Issuance of Preferred Stock
Comparable Companies
ADTX CPMV VRAX NLSP XBIO CMND CDT SNGX SILO OGEN VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
109 W Main Street, Dalton, OH, USA, 44618
Website
https://www.protokinetix.com
ProtoKinetix Inc is a research and development stage biotechnology company focused on scientific medical research of AFGPs (Anti-Freeze Glycoproteins). The AFGP is a compound produced by fish, insects, reptiles, bacteria, and plants that enable survival in freezing temperatures. The company also develops AFGP applications which include regenerative medicine issues including harvesting, processing, storage, and transplanting cells, tissues, and organs and treatments for chronic inflammatory conditions and diseases caused by stress factors, including UV radiation, oxidation, and cryopreservation and hydrogen peroxide.
Executives
Clarence Edward Smith director, 10 percent owner, officer: President & CEO 1845 COUNTY ROAD #214, ST. AUGUSTINE FL 32084
Michael Richard Guzzetta officer: CFO 412 MULBERRY STREET, MARIETTA OH 45750
Lachlan Grant Young 10 percent owner 6438 ROSEBERY AVE., WEST VANCOUVER A1 V7W2C6
Edward P. Mcdonough director 1226 WASHINGTON AVENUE, PARKERSBURG WV 26101
Susan Marie Woodward officer: CFO 705 DUGAN ROAD, BELPRE OH 45714
Peter Krogh Jensen director 4656 HOSKINS ROAD, NORTH VANCOUVER A1 V7K 2R1
Ian Thomas Gregory director 2225 FOLKESTONE WAY, WEST VANCOUVER A1 V7S 2Y6
Ross Laurence Senior director, officer: CEO PH-3, 5688 DALHOUISE ROAD, VANCOUVER A1 V6T 1W4
Mark L Baum director, officer: President C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130

ProtoKinetix Headlines

From GuruFocus

Insider Buying: ProtoKinetix Inc CEO and 10% Owner Clarence Smith Acquires 3,750,000 Shares

By GuruFocus Research GuruFocus Editor • 05-25-2023

Insider Buying: ProtoKinetix Inc CEO and 10% Owner Clarence Smith Acquires 3,750,000 Shares

By GuruFocus Research • 05-26-2023